![Dr Charles Harrington Dr Charles Harrington](/img/200x200/staffpages/uploads/men133/avatar/kBqwgKooixTI7MNVVdJc5pUUCNjCSdzdKOJ7rv3M.jpeg)
BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)
Senior Research Fellow
- About
-
- Email Address
- c.harrington@abdn.ac.uk
- Telephone Number
- +44 (0)1224 438563
- Office Address
Liberty Building, Institute of Medical Sciences, Foresterhill Road, Aberdeen AB25 2ZP United Kingdom
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He completed his PhD working with Dr Julia Douglas on cell wall synthesis in yeast and followed with a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow, where he spent four years investigating the synthesis of bacterial cell wall polymers. Dr Harrington then spent over two years at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.
In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology. Working in the Cambridge Brain Bank Laboratory over a period of 10 years. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed as a Senior Research Fellow.
The Alzheimer's research was translated to the clinic, through a spin-out company, TauRx Therapeutics, who are conducting phase 3 trials of hydromethylthionine. Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd responsible for the non-clinical activities of the company.
Qualifications
- BSc (Hons) Microbiology1977 - University of Glasgow
- PhD Microbiology1980 - University of Glasgow
Latest Publications
Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine
Cellular Signalling, 111269Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.cellsig.2024.111269
Hydromethylthionine rescues synaptic SNARE proteins in a mouse model of tauopathies: interference by cholinesterase inhibitors
Brain Research Bulletin, vol. 212, 110955Contributions to Journals: ArticlesConsiderations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
Translational neurodegeneration, vol. 13, 25Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.1186/s40035-024-00417-w
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/23668/1/s40035-024-00417-w.pdf
LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy
European Journal of Pharmacology, vol. 970, 176505Contributions to Journals: ArticlesNeuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model
Cells, vol. 13, no. 7, 642Contributions to Journals: Articles
- Research
-
Research Overview
Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.
- Publications
-
Page 3 of 4 Results 51 to 75 of 98
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
The Lancet, vol. 388, no. 10062, pp. 2873-2884Contributions to Journals: ArticlesInhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease
Developing Therapeutics for Alzheimer's Disease: Progress and Challenges. Wolfe, M. S. (ed.). Elsevier Inc., pp. 385-436, 52 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1016/B978-0-12-802173-6.00015-0
- [ONLINE] View publication in Scopus
Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease
Biomolecules, vol. 6, no. 2, pp. 1-19Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3390/biom6020019
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/5864/1/biomolecules_06_00019_v2.pdf
Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies
Biomolecules, vol. 6, no. 1, 6Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.3390/biom6010006
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/8985/1/biomolecules_06_00006_v2.pdf
- [ONLINE] View publication in Scopus
Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration
Cellular and Molecular Life Sciences, vol. 72, no. 11, pp. 2199-2222Contributions to Journals: ArticlesEffects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
Behavioural Pharmacology, vol. 26, no. 4, pp. 353-368Contributions to Journals: ArticlesCellular Models of Aggregation-Dependent Template-Directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer's Disease
The Journal of Biological Chemistry, vol. 290, no. 17, pp. 10862-10875Contributions to Journals: ArticlesThe relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease
Frontiers in Neuroscience, vol. 9, 33Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3389/fnins.2015.00033
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4290/1/fnins_09_00033.pdf
Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease
Journal of Alzheimer's Disease, vol. 44, no. 2, pp. 705-720Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3233/JAD-142874
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4205/1/fulltext.pdf
Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease
Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 1, pp. 110-118Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1124/jpet.114.219352
Tau-aggregation inhibitor therapy for Alzheimer's disease
Biochemical Pharmacology, vol. 88, no. 4, pp. 529-539Contributions to Journals: ArticlesTauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX
13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, pp. S26Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1016/j.neurobiolaging.2014.01.128
Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function
Neurobiology of Aging, vol. 34, no. 5, pp. 1380-1388Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.neurobiolaging.2012.11.007
New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromes
Patents: PatentsThe molecular pathology of Alzheimer's disease
Neuroimaging Clinics of North America, vol. 22, no. 1, pp. 11-22Contributions to Journals: Literature Reviews- [ONLINE] DOI: https://doi.org/10.1016/j.nic.2011.11.003
3,7-diamino-10H-phenothiazine salts and their use: WO2007110627
Patents: PatentsStripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T
Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 24, no. 6, pp. 331-337Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s10334-011-0273-8
3,6-Disubstituted xanthylium salts
Patents: PatentsMethods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compounds
Patents: PatentsLigands for aggregated tau molecules: WO2010034982
Patents: PatentsRationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies
Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. Martinez, A. (ed.), pp. 210-232, 23 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1039/9781849731065
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4066/1/Wischik_2010_RSC_Chapter.pdf
Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe
The Scientific World Journal, vol. 9, pp. 1463-1475Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1100/tsw.2009.151
What is the molecular pathology that underlies hippocampal memory decline?
Journal of Neurology, Neurosurgery & Psychiatry, vol. 80, no. 7, pp. 703Contributions to Journals: EditorialsTherapeutic Use of Diaminophenothiazines: WO2009044127
Patents: PatentsMethylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine
Psychopharmacology, vol. 202, no. 1-3, pp. 53-65Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s00213-008-1394-2